Volume 19 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(1): 10-13
LI Ran, XIE Li-juan, JIAO Chang-qing, LU Hong-hong, ZHOU Bi-rong. Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with different ejection fraction[J]. Chinese Journal of General Practice, 2021, 19(1): 10-13. doi: 10.16766/j.cnki.issn.1674-4152.001716
Citation: LI Ran, XIE Li-juan, JIAO Chang-qing, LU Hong-hong, ZHOU Bi-rong. Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with different ejection fraction[J]. Chinese Journal of General Practice, 2021, 19(1): 10-13. doi: 10.16766/j.cnki.issn.1674-4152.001716
shu

Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with different ejection fraction

doi: 10.16766/j.cnki.issn.1674-4152.001716

  • Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, China

Funds:

 2018-TG03

 KJ2018A0708

 2017H118

  • Received Date: 2020-08-25
    Available Online: 2022-02-19
    Abstract
  •   Objective  To observe the clinical effect, prognosis and safety of sacubitril-valsartan in treating chronic heart failure (CHF) patients with different ejection fraction.   Methods  Seventy-eight patients were obtained from the Department of Cardiology of The First Affiliated Hospital of Anhui Medical University from January 2019 to December 2019. The patients were divided into the HFrEF group and HFpEF group on the basis of ejection fraction: 40 patients in the HFrEF group and 38 patients in the HFpEF group. All patients were treated with sacubitril-valsartan on the basis of routine heart failure treatment. Brain natriuretic peptide (BNP), renal function, serum potassium, left ventricular ejection fraction (LVEF), left atrial diameter (LAD), left ventricular end diastolic diameter (LVEDD) and New York heart function classification (NYHA) of both groups were compared after 6 months of treatment. Treatment safety was also assessed. The end point event was cardiovascular death or hospitalisation for worsening heart failure. The accumulated end-point event-free survival rate in 6 months between the two groups was compared by the Kaplan-Meier survival curve method.   Results  After 6 months of treatment, the HFrEF group showed significantly decreased BNP, LAD and LVEDD; significantly increased LVEF and significantly improved NYHA classification (all P < 0.05) compared with that before treatment. After 6 months of treatment, the HFpEF group also showed significantly decreased BNP, LAD and LVEDD; significantly increased LVEF and significantly improved NYHA classification (all P < 0.05) compared with that before treatment. However, the degree of decrease in the BNP levels and improvement in NYHA class were better in the HFrEF group than that in the HFpEF group. No difference in cumulative event-free survival was found between the HFrEF and HFpEF groups (81.9% vs. 85.0%, P=0.694). Safety was good in both groups.   Conclusion  Sacubitril-valsartan has a certain effect on heart failure with preserved ejection fraction, which shows potential clinical application, but it is slightly less effective on heart failure with reduced ejection fraction. There is no significant difference in prognosis and safety between the two groups.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    PONIKOWSKI P, VOORS A A, ANKER S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016, 18(8): 891-975. doi: 10.1002/ejhf.592
    [2]
    KHDER Y, SHI V, MCMURRAY J, et al. Sacubitril/Valsartan (LCZ696) in heart failure[J]. Handb Exp Pharmacol, 2017, 243: 133-165. http://www.ncbi.nlm.nih.gov/pubmed/28004291
    [3]
    MCMURRAY J J, PACKER M, DESAI A S, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11): 993-1004. doi: 10.1056/NEJMoa1409077
    [4]
    SOLOMON S D, MCMURRAY J J V, ANAND I S, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019, 381(17): 1609-1620. doi: 10.1056/NEJMoa1908655
    [5]
    中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
    [6]
    廖玉华, 杨杰孚, 张健, 等. 舒张性心力衰竭诊断和治疗专家共识[J]. 临床心血管病杂志, 2020, 36(1): 1-10. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202001001.htm
    [7]
    PIESKE B, TSCHÖPE C, DE BOER R A, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)[J]. Eur J Heart Fail, 2020, 22(3): 391-412. doi: 10.1002/ejhf.1741
    [8]
    IBRAHIM N E, SONG Y, CANNON C P, et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry (R)[J]. ESC Heart Fail, 2019, 6(4): 784-792. doi: 10.1002/ehf2.12455
    [9]
    GLADDEN J, CHAANINE A H, REDFIELD M M. Heart failure with preserved ejection fraction[J]. Annu Rev Med, 2018, 69: 65-79. doi: 10.1146/annurev-med-041316-090654
    [10]
    HAN Y, AYALASOMAYAJULA S, PAN W, et al. Pharmacokinetics, safety and tolerability of Sacubitril/Valsartan (LCZ696) after single-dose administration in healthy Chinese subjects[J]. Eur J Drug Metab Pharmacokinet, 2017, 42(1): 109-116. doi: 10.1007/s13318-016-0328-3
    [11]
    ESTEBAN-FERNáNDEZ A, DíEZ-VILLANUEVA P, VICENT L, et al. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort[J]. Rev Esp Geriatr Gerontol, 2020, 55(2): 65-69. doi: 10.1016/j.regg.2019.10.002
    [12]
    PASCUAL-FIGAL D, WACHTER R, SENNI M, et al. NT-proBNP response to Sacubitril/Valsartan in hospitalized heart failure patients with reduced ejection fraction: TRANSITION study[J]. JACC Heart Fail, 2020, 8(10): 822-833. doi: 10.1016/j.jchf.2020.05.012
    [13]
    CUNNINGHAM J W, VADUGANATHAN M, CLAGGETT B L, et al. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type natriuretic peptide in heart failure with preserved ejection fraction[J]. JACC Heart Fail, 2020, 8(5): 372-381. doi: 10.1016/j.jchf.2020.03.002
    [14]
    VADUGANATHAN M, JHUND P S, CLAGGETT B L, et al. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction[J]. Eur Heart J, 2020, 41(25): 2356-2362. doi: 10.1093/eurheartj/ehaa184
    [15]
    SHAH K S, XU H L, MATSOUAKA R A, et al. Heart failure with preserved, borderline, and reduced ejection fraction 5-year outcomes[J]. J Am Coll Cardiol, 2017, 70(20): 2476-2486. doi: 10.1016/j.jacc.2017.08.074
    [16]
    HOONG C W, LIM C P, GAO F, et al. Outcomes of heart failure with preserved ejection fraction in a Southeast Asian cohort[J]. J Cardiovasc Med (Hagerstown), 2015, 16(9): 583-590. doi: 10.2459/JCM.0000000000000100
    [17]
    HSIAO F C, WANG C L, CHANG P C, et al. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience from Taiwan[J]. J Cardiovasc Pharmacol Ther, 2020, 25(2): 152-157. doi: 10.1177/1074248419872958
    [18]
    TRIPOSKIADIS F, BUTLER J, ABBOUD F M, et al. The continuous heart failure spectrum: moving beyond an ejection fraction classification[J]. Eur Heart J, 2019, 40(26): 2155-2163. doi: 10.1093/eurheartj/ehz158
    [19]
    GE J B. Coding proposal on phenotyping heart failure with preserved ejection fraction: A practical tool for facilitating etiology-oriented therapy[J]. Cardiol J, 2020, 27(1): 97-98. doi: 10.5603/CJ.2020.0023
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (442) PDF downloads(18) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return